{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:23:54Z","timestamp":1791563034056,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41409-020-0940-3","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T06:02:39Z","timestamp":1590213759000},"page":"2254-2260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma"],"prefix":"10.1038","volume":"55","author":[{"name":"On behalf of IFM (Intergroupe Fran\u00e7ais du My\u00e9lome \u2013 IFM 2014-05)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-2823","authenticated-orcid":false,"given":"Zo\u00e9","family":"Van de Wyngaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Nerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillemette","family":"Fouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lorraine","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabih","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lenain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramdane","family":"Belhocine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Systchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Gruchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Princet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-8088","authenticated-orcid":false,"given":"Erik","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Limat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"issue":"suppl_4","key":"940_CR1","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol \/ ESMO. 2017;28(suppl_4):iv52\u2013iv61.","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol \/ ESMO"},{"key":"940_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(96)90536-X","volume":"347","author":"N Schmitz","year":"1996","unstructured":"Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353\u20137.","journal-title":"Lancet"},{"key":"940_CR3","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1182\/blood.V86.10.3961.bloodjournal86103961","volume":"86","author":"CH Weaver","year":"1995","unstructured":"Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961\u20139.","journal-title":"Blood"},{"key":"940_CR4","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2009.127","volume":"23","author":"S Giralt","year":"2009","unstructured":"Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904\u201312.","journal-title":"Leukemia"},{"key":"940_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","volume":"20","author":"A Alegre","year":"1997","unstructured":"Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernandez JJ, Fernandez-Villalta MJ, Arranz R, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transpl. 1997;20:211\u20137.","journal-title":"Bone Marrow Transpl."},{"key":"940_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/bmt.2008.369","volume":"43","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transpl. 2009;43:619\u201325.","journal-title":"Bone Marrow Transpl."},{"key":"940_CR7","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720\u20136.","journal-title":"Blood"},{"key":"940_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3816\/SCT.2004.n.008","volume":"1","author":"K Hubel","year":"2004","unstructured":"Hubel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S, et al. Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. Support Cancer Ther. 2004;1:165\u201372.","journal-title":"Support Cancer Ther"},{"key":"940_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/sj.bmt.1702408","volume":"25","author":"PG Dyson","year":"2000","unstructured":"Dyson PG, Horvath N, Joshua D, Barrow L, Van Holst NG, Brown R, et al. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma. Bone Marrow Transpl. 2000;25:1175\u201384.","journal-title":"Bone Marrow Transpl"},{"key":"940_CR10","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","volume":"19","author":"AK Stewart","year":"2001","unstructured":"Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771\u20139.","journal-title":"J Clin Oncol"},{"key":"940_CR11","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood"},{"key":"940_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/14653240701508429","volume":"9","author":"M Putkonen","year":"2007","unstructured":"Putkonen M, Rauhala A, Pelliniemi TT, Remes K. Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma. Cytotherapy. 2007;9:548\u201354.","journal-title":"Cytotherapy"},{"key":"940_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/bmt.2015.322","volume":"51","author":"S Afifi","year":"2016","unstructured":"Afifi S, Adel NG, Devlin S, Duck E, Vanak J, Landau H, et al. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transpl. 2016;51:546\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"940_CR14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21280","volume":"28","author":"L Chaudhary","year":"2013","unstructured":"Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013;28:359\u201367.","journal-title":"J Clin Apher"},{"key":"940_CR15","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","volume":"39","author":"CG Pelligra","year":"2017","unstructured":"Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, et al. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. Clin Ther. 2017;39:1986\u20132005 e5.","journal-title":"Clin Ther"},{"key":"940_CR16","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1080\/10428194.2017.1393673","volume":"59","author":"C Greil","year":"2018","unstructured":"Greil C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, Kuhbach K, Bosse R, et al. Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. Leuk Lymphoma. 2018;59:1722\u20135.","journal-title":"Leuk Lymphoma"},{"key":"940_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/ijlh.13142","volume":"42","author":"JR Furundarena","year":"2020","unstructured":"Furundarena JR, Uranga A, Alkorta A, Gonzalez C, Javier Ferreiro J, Rey M, et al. Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield. Int J Lab Hematol. 2020;42:170\u20139. https:\/\/doi.org\/10.1111\/ijlh.13142.","journal-title":"Int J Lab Hematol"},{"key":"940_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bbmt.2018.01.039","volume":"24","author":"IN Micallef","year":"2018","unstructured":"Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, et al. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transpl. 2018;24:1187\u201395.","journal-title":"Biol Blood Marrow Transpl"},{"key":"940_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","volume":"6","author":"D Dingli","year":"2006","unstructured":"Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma. 2006;6:384\u20138.","journal-title":"Clin Lymphoma Myeloma"},{"key":"940_CR20","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/bmt.2015.190","volume":"50","author":"GL Uy","year":"2015","unstructured":"Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, et al. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transpl. 2015;50:1513\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"940_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3324\/haematol.2011.043372","volume":"97","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012;97:442\u201350.","journal-title":"Haematologica"},{"key":"940_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","volume":"137","author":"GJ Morgan","year":"2007","unstructured":"Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 2007;137:268\u20139.","journal-title":"Br J Haematol"},{"key":"940_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"940_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"940_CR25","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32:2712\u20137.","journal-title":"J Clin Oncol"},{"key":"940_CR26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjh.15002","volume":"183","author":"H Takamatsu","year":"2018","unstructured":"Takamatsu H, Wee RK, Zaimoku Y, Murata R, Zheng J, Moorhead M, et al. A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. Br J Haematol. 2018;183:664\u20138.","journal-title":"Br J Haematol"},{"key":"940_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bmt.2010.170","volume":"46","author":"LJ Costa","year":"2011","unstructured":"Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transpl. 2011;46:523\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"940_CR28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","volume":"17","author":"P Shaughnessy","year":"2011","unstructured":"Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transpl. 2011;17:729\u201336.","journal-title":"Biol Blood Marrow Transpl"},{"key":"940_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41409-017-0033-0","volume":"53","author":"M Mohty","year":"2018","unstructured":"Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, et al. Plerixafor in poor mobilizers with non-Hodgkin\u2019s lymphoma: a multi-center time-motion analysis. Bone Marrow Transpl. 2018;53:246\u201354.","journal-title":"Bone Marrow Transpl"},{"key":"940_CR30","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1080\/10428194.2016.1271946","volume":"58","author":"C Greil","year":"2017","unstructured":"Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, et al. Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. Leuk Lymphoma. 2017;58:1849\u201358.","journal-title":"Leuk Lymphoma"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0940-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:19:57Z","timestamp":1722928797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0940-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0940-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LK, PM, CH have no relevant conflict of interest to disclose. XL declares honorarium from Sanofi. ZVDW, VN, GF, MLC, DC, NA, LG, PL, MM, JHB, RB, AJ, AB, NM, TS, CGr, CGi, SG, CD, IP, CT, ED, SL have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}